Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lifestyle overhaul may rewrite Sperm's epigenetic code

NCT ID NCT04175678

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how diet and exercise affect the epigenome—chemical marks on DNA—in sperm of overweight Hispanic men. Researchers will compare sperm from 20 healthy active men and 80 obese inactive men before and after a 12-week program of diet, exercise, or both. They will also check if changes last after stopping the interventions. The goal is to understand if a healthier lifestyle can reverse harmful epigenetic changes that might affect fertility and future children's health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
diet and exercise
What this could lead to
If successful, this could show that lifestyle changes can reverse unhealthy epigenetic marks in sperm, potentially improving fertility and reducing disease risk in children.
What could go wrong
This is an early-stage observational and interventional study with only 100 participants, all Hispanic men, so results may not apply to other groups. The long-term health impact on offspring is not directly tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2020

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine within the reference range at the time of screening 2. Must have Hispanic Father and Mother from Mexico or Central America 3. Normal weight, active subjects: * BMI 18.5 - 24.9 calculated as weight in Kg/ (height in cm)2 * Participates in ≥150 min/week of moderate intensity physical activity as assessed by accelerometer * Consume \< 30% of calories as fat/day * Fasting lipid panel within reference range or not clinically significant above the reference ranges Obese and physically inactive subjects: * BMI ≥ 30 calculated as weight in Kg/ (height in cm)2 in obese subjects * Have risk factors for developing type 2 diabetes (first degree relatives with Diabetes Mellitus type 2, BP≥130/80, HDL-cholesterol ≤ 35mg/dL or triglycerides ≥200mg/dL, fasting plasma glucose ≥100mg/dl to 125mg/dL or HgbA1c ≥ 5.7 to 6.4%, abnormal liver transaminases (not more than 3 times upper limit of normal suggestive of hepatic steatosis) * Participates in ≤150 min/week of moderate intensity physical activity * Consume \>30 % fat as calories/day * Stable weight for past six months prior to the first screening visit * Willing to commit to 12 weeks of three times a week personalized exercise training * Willing to commit to 12 weeks of weight loss diet (low fat and low calories) 4. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form 5. Does not meet any of the exclusion criteria. Exclusion Criteria: 1. Men who meet any of the following criteria are NOT eligible for enrollment in the trial: 2. Men participating in another clinical trial within the last 30 days prior to the first screening visit 3. Men not living in the catchment's area of the clinic or within a reasonable distance from the site 4. Clinically significant abnormal findings at screening except for those stated above for the obese, inactive group 5. Abnormal serum chemistry values, according to local laboratory normal values that indicate chronic liver or kidney dysfunction or that may be considered clinically significant (except for obesity related abnormal laboratory tests including blood glucose, Hgb A1c, liver transaminases, lipids for the obese, active group as stated above). Other abnormal lab values may also be exclusionary, at the discretion of the investigator 6. Sperm concentration below 15 million/mL in more than one of three screening samples 7. Diastolic (D) blood pressure (BP) \> 30 and Systolic (S) BP \> 130 mm Hg for the healthy, non-obese and active group; and diastolic (D) blood pressure (BP) \> 150 and Systolic (S) BP \> 100 mm Hg for the obese, inactive group on in the opinion of the investigator not suitable for exercise training (BP will be taken 3 times at 5 minute intervals and the mean of all measurements be considered) 8. History of hypertension, including hypertension controlled with treatment in the healthy, active group 9. Known history of reproductive dysfunction including vasectomy or infertility 10. Known history of cardiac, renal, hepatic, cardiac or respiratory disease 11. A serious systemic disease such as diabetes mellitus defined by the American Diabetes Association or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above) 12. Known or suspected alcoholism or drug abuse or chronic infections 13. Serious digestive and/or absorptive problems, including inflammatory bowel disease and 14. Chronic food intolerance or diarrhea that preclude adherence to the study diet. 15. Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. 16. Psychiatric disorders (including eating disorders) or conditions that, in the opinion of the investigator, would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder). 17. History of other malignancies except: adequately treated non-melanoma skin cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy lifestyle are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Lundquist Institute

    Torrance, California, 90502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.